Skip to main content
PMC home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 2002 Aug;73(2):121–125. doi: 10.1136/jnnp.73.2.121

Reproductive dysfunction in women with epilepsy: recommendations for evaluation and management

J Bauer 1, J Isojarvi 1, A Herzog 1, M Reuber 1, D Polson 1, E Tauboll 1, P Genton 1, H van der Ven 1, B Roesing 1, G Luef 1, C Galimberti 1, J van Parys 1, D Flugel 1, A Bergmann 1, C Elger 1
PMCID: PMC1737978  PMID: 12122167

Abstract

Background: Epilepsy is commonly associated with reproductive endocrine disorders. These include polycystic ovary syndrome (PCOS), isolated components of this syndrome such as polycystic ovaries, hyperandrogenaemia, hypothalamic amenorrhoea, and functional hyperprolactinaemia.

Objective: To summarise the currently known relations between epilepsy and reproductive endocrine disorders.

Methods: A review of clinical experience and published reports.

Results: The most likely explanations for endocrine disorders related to epilepsy or antiepileptic drugs are: (1) a direct influence of the epileptogenic lesion, epilepsy, or antiepileptic drugs on the endocrine control centres in the brain; (2) the effects of antiepileptic drugs on peripheral endocrine glands; (3) the effects of antiepileptic drugs on the metabolism of hormones and binding proteins; and (4) secondary endocrine complications of antiepileptic drug related weight changes or changes of insulin sensitivity. Regular monitoring of reproductive function at visits is recommended, including questioning about menstrual disorders, fertility, weight, hirsutism, and galactorrhoea. Particular attention should be paid to patients on valproate and obese patients or those experiencing significant weight gain. Single abnormal laboratory or imaging findings without symptoms may not constitute a clinically relevant endocrine disorder. However, patients with these kinds of abnormalities should be monitored to detect the possible development of a symptomatic disorder associated with, for example, menstrual disorders or fertility problems.

Conclusions: If a reproductive endocrine disorder is found, antiepileptic drug treatment should be reviewed to ensure that it is correct for the particular seizure type and that it is not contributing to the endocrine problem. The possible benefits of a change in treatment must be balanced against seizure control and the cumulative side effect of alternative agents.

Full Text

The Full Text of this article is available as a PDF (108.1 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Balen A. Pathogenesis of polycystic ovary syndrome--the enigma unravels? Lancet. 1999 Sep 18;354(9183):966–967. doi: 10.1016/S0140-6736(99)00218-4. [DOI] [PubMed] [Google Scholar]
  2. Barragry J. M., Makin H. L., Trafford D. J., Scott D. F. Effect of anticonvulsants on plasma testosterone and sex hormone binding globulin levels. J Neurol Neurosurg Psychiatry. 1978 Oct;41(10):913–914. doi: 10.1136/jnnp.41.10.913. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bauer J. Epilepsy and prolactin in adults: a clinical review. Epilepsy Res. 1996 May;24(1):1–7. doi: 10.1016/0920-1211(96)00009-5. [DOI] [PubMed] [Google Scholar]
  4. Bauer J., Jarre A., Klingmüller D., Elger C. E. Polycystic ovary syndrome in patients with focal epilepsy: a study in 93 women. Epilepsy Res. 2000 Sep;41(2):163–167. doi: 10.1016/s0920-1211(00)00139-x. [DOI] [PubMed] [Google Scholar]
  5. Bauer J., Stefan H., Schrell U., Uhlig B., Landgraf S., Neubauer U., Neundörfer B., Burr W. Serum prolactin concentrations and epilepsy. A study which compares healthy subjects with a group of patients in presurgical evaluation and circadian variations with those related to seizures. Eur Arch Psychiatry Clin Neurosci. 1992;241(6):365–371. doi: 10.1007/BF02191962. [DOI] [PubMed] [Google Scholar]
  6. Bauer J., Stoffel-Wagner B., Flügel D., Kluge M., Elger C. E. The impact of epilepsy surgery on sex hormones and the menstrual cycle in female patients. Seizure. 2000 Sep;9(6):389–393. doi: 10.1053/seiz.2000.0434. [DOI] [PubMed] [Google Scholar]
  7. Beastall G. H., Cowan R. A., Gray J. M., Fogelman I. Hormone binding globulins and anticonvulsant therapy. Scott Med J. 1985 Apr;30(2):101–105. doi: 10.1177/003693308503000206. [DOI] [PubMed] [Google Scholar]
  8. Biton V., Mirza W., Montouris G., Vuong A., Hammer A. E., Barrett P. S. Weight change associated with valproate and lamotrigine monotherapy in patients with epilepsy. Neurology. 2001 Jan 23;56(2):172–177. doi: 10.1212/wnl.56.2.172. [DOI] [PubMed] [Google Scholar]
  9. Breum L., Astrup A., Gram L., Andersen T., Stokholm K. H., Christensen N. J., Werdelin L., Madsen J. Metabolic changes during treatment with valproate in humans: implication for untoward weight gain. Metabolism. 1992 Jun;41(6):666–670. doi: 10.1016/0026-0495(92)90061-e. [DOI] [PubMed] [Google Scholar]
  10. Brodie M. J., French J. A. Management of epilepsy in adolescents and adults. Lancet. 2000 Jul 22;356(9226):323–329. doi: 10.1016/S0140-6736(00)02515-0. [DOI] [PubMed] [Google Scholar]
  11. Bäckström T. Epileptic seizures in women related to plasma estrogen and progesterone during the menstrual cycle. Acta Neurol Scand. 1976 Oct;54(4):321–347. doi: 10.1111/j.1600-0404.1976.tb04363.x. [DOI] [PubMed] [Google Scholar]
  12. Dana-Haeri J., Trimble M. r., Oxley J. Prolactin and gonadotrophin changes following generalised and partial seizures. J Neurol Neurosurg Psychiatry. 1983 Apr;46(4):331–335. doi: 10.1136/jnnp.46.4.331. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Eagleson C. A., Gingrich M. B., Pastor C. L., Arora T. K., Burt C. M., Evans W. S., Marshall J. C. Polycystic ovarian syndrome: evidence that flutamide restores sensitivity of the gonadotropin-releasing hormone pulse generator to inhibition by estradiol and progesterone. J Clin Endocrinol Metab. 2000 Nov;85(11):4047–4052. doi: 10.1210/jcem.85.11.6992. [DOI] [PubMed] [Google Scholar]
  14. Gregoraszczuk E., Wójtowicz A. K., Taubøll E., Ropstad E. Valproate-induced alterations in testosterone, estradiol and progesterone secretion from porcine follicular cells isolated from small- and medium-sized ovarian follicles. Seizure. 2000 Oct;9(7):480–485. doi: 10.1053/seiz.2000.0443. [DOI] [PubMed] [Google Scholar]
  15. Herzog A. G. A relationship between particular reproductive endocrine disorders and the laterality of epileptiform discharges in women with epilepsy. Neurology. 1993 Oct;43(10):1907–1910. doi: 10.1212/wnl.43.10.1907. [DOI] [PubMed] [Google Scholar]
  16. Herzog A. G., Klein P., Ransil B. J. Three patterns of catamenial epilepsy. Epilepsia. 1997 Oct;38(10):1082–1088. doi: 10.1111/j.1528-1157.1997.tb01197.x. [DOI] [PubMed] [Google Scholar]
  17. Herzog A. G., Schachter S. C. Valproate and the polycystic ovarian syndrome: final thoughts. Epilepsia. 2001 Mar;42(3):311–315. doi: 10.1046/j.1528-1157.2001.33500.x. [DOI] [PubMed] [Google Scholar]
  18. Herzog A. G., Seibel M. M., Schomer D. L., Vaitukaitis J. L., Geschwind N. Reproductive endocrine disorders in women with partial seizures of temporal lobe origin. Arch Neurol. 1986 Apr;43(4):341–346. doi: 10.1001/archneur.1986.00520040029014. [DOI] [PubMed] [Google Scholar]
  19. Herzog A. G., Seibel M. M., Schomer D., Vaitukaitis J., Geschwind N. Temporal lobe epilepsy: an extrahypothalamic pathogenesis for polycystic ovarian syndrome? Neurology. 1984 Oct;34(10):1389–1393. doi: 10.1212/wnl.34.10.1389. [DOI] [PubMed] [Google Scholar]
  20. Isojärvi J. I., Laatikainen T. J., Knip M., Pakarinen A. J., Juntunen K. T., Myllylä V. V. Obesity and endocrine disorders in women taking valproate for epilepsy. Ann Neurol. 1996 May;39(5):579–584. doi: 10.1002/ana.410390506. [DOI] [PubMed] [Google Scholar]
  21. Isojärvi J. I., Laatikainen T. J., Pakarinen A. J., Juntunen K. T., Myllylä V. V. Menstrual disorders in women with epilepsy receiving carbamazepine. Epilepsia. 1995 Jul;36(7):676–681. doi: 10.1111/j.1528-1157.1995.tb01045.x. [DOI] [PubMed] [Google Scholar]
  22. Isojärvi J. I., Laatikainen T. J., Pakarinen A. J., Juntunen K. T., Myllylä V. V. Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy. N Engl J Med. 1993 Nov 4;329(19):1383–1388. doi: 10.1056/NEJM199311043291904. [DOI] [PubMed] [Google Scholar]
  23. Isojärvi J. I., Pakarinen A. J., Myllylä V. V. A prospective study of serum sex hormones during carbamazepine therapy. Epilepsy Res. 1991 Jul;9(2):139–144. doi: 10.1016/0920-1211(91)90025-b. [DOI] [PubMed] [Google Scholar]
  24. Isojärvi J. I., Pakarinen A. J., Rautio A., Pelkonen O., Myllylä V. V. Serum sex hormone levels after replacing carbamazepine with oxcarbazepine. Eur J Clin Pharmacol. 1995;47(5):461–464. doi: 10.1007/BF00196862. [DOI] [PubMed] [Google Scholar]
  25. Isojärvi J. I., Pakarinen A. J., Ylipalosaari P. J., Myllylä V. V. Serum hormones in male epileptic patients receiving anticonvulsant medication. Arch Neurol. 1990 Jun;47(6):670–676. doi: 10.1001/archneur.1990.00530060082023. [DOI] [PubMed] [Google Scholar]
  26. Isojärvi J. I., Rättyä J., Myllylä V. V., Knip M., Koivunen R., Pakarinen A. J., Tekay A., Tapanainen J. S. Valproate, lamotrigine, and insulin-mediated risks in women with epilepsy. Ann Neurol. 1998 Apr;43(4):446–451. doi: 10.1002/ana.410430406. [DOI] [PubMed] [Google Scholar]
  27. Isojärvi J. I. Serum steroid hormones and pituitary function in female epileptic patients during carbamazepine therapy. Epilepsia. 1990 Jul-Aug;31(4):438–445. doi: 10.1111/j.1528-1157.1990.tb05500.x. [DOI] [PubMed] [Google Scholar]
  28. Isojärvi J. I., Taubøll E., Pakarinen A. J., van Parys J., Rättyä J., Harbo H. F., Dale P. O., Fauser B. C., Gjerstad L., Koivunen R. Altered ovarian function and cardiovascular risk factors in valproate-treated women. Am J Med. 2001 Sep;111(4):290–296. doi: 10.1016/s0002-9343(01)00806-3. [DOI] [PubMed] [Google Scholar]
  29. Klein P., Serje A., Pezzullo J. C. Premature ovarian failure in women with epilepsy. Epilepsia. 2001 Dec;42(12):1584–1589. doi: 10.1046/j.1528-1157.2001.13701r.x. [DOI] [PubMed] [Google Scholar]
  30. Knochenhauer E. S., Key T. J., Kahsar-Miller M., Waggoner W., Boots L. R., Azziz R. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab. 1998 Sep;83(9):3078–3082. doi: 10.1210/jcem.83.9.5090. [DOI] [PubMed] [Google Scholar]
  31. Luef G., Abraham I., Trinka E., Alge A., Windisch J., Daxenbichler G., Unterberger I., Seppi K., Lechleitner M., Krämer G. Hyperandrogenism, postprandial hyperinsulinism and the risk of PCOS in a cross sectional study of women with epilepsy treated with valproate. Epilepsy Res. 2002 Jan;48(1-2):91–102. doi: 10.1016/s0920-1211(01)00317-5. [DOI] [PubMed] [Google Scholar]
  32. Luef G., Abraham I., Trinka E., Unterberger I., Hoppichler F., Bauer G., Lechleitner M. Weight change associated with valproate and lamotrigine monotherapy in patients with epilepsy. Neurology. 2001 Aug 14;57(3):565–566. doi: 10.1212/wnl.57.3.565-a. [DOI] [PubMed] [Google Scholar]
  33. Michelmore K. F., Balen A. H., Dunger D. B., Vessey M. P. Polycystic ovaries and associated clinical and biochemical features in young women. Clin Endocrinol (Oxf) 1999 Dec;51(6):779–786. doi: 10.1046/j.1365-2265.1999.00886.x. [DOI] [PubMed] [Google Scholar]
  34. Molaie M., Culebras A., Miller M. Effect of interictal epileptiform discharges on nocturnal plasma prolactin concentrations in epileptic patients with complex partial seizures. Epilepsia. 1986 Nov-Dec;27(6):724–728. doi: 10.1111/j.1528-1157.1986.tb03601.x. [DOI] [PubMed] [Google Scholar]
  35. Murialdo G., Galimberti C. A., Gianelli M. V., Rollero A., Polleri A., Copello F., Magri F., Ferrari E., Sampaolo P., Manni R. Effects of valproate, phenobarbital, and carbamazepine on sex steroid setup in women with epilepsy. Clin Neuropharmacol. 1998 Jan-Feb;21(1):52–58. [PubMed] [Google Scholar]
  36. Murialdo G., Galimberti C. A., Magri F., Sampaolo P., Copello F., Gianelli M. V., Gazzerro E., Rollero A., Deagatone C., Manni R. Menstrual cycle and ovary alterations in women with epilepsy on antiepileptic therapy. J Endocrinol Invest. 1997 Oct;20(9):519–526. doi: 10.1007/BF03348013. [DOI] [PubMed] [Google Scholar]
  37. Olafsson E., Hauser W. A., Gudmundsson G. Fertility in patients with epilepsy: a population-based study. Neurology. 1998 Jul;51(1):71–73. doi: 10.1212/wnl.51.1.71. [DOI] [PubMed] [Google Scholar]
  38. Pijl H., Meinders A. E. Bodyweight change as an adverse effect of drug treatment. Mechanisms and management. Drug Saf. 1996 May;14(5):329–342. doi: 10.2165/00002018-199614050-00005. [DOI] [PubMed] [Google Scholar]
  39. Polson D. W., Adams J., Wadsworth J., Franks S. Polycystic ovaries--a common finding in normal women. Lancet. 1988 Apr 16;1(8590):870–872. doi: 10.1016/s0140-6736(88)91612-1. [DOI] [PubMed] [Google Scholar]
  40. Rättyä J., Pakarinen A. J., Knip M., Repo-Outakoski M., Myllylä V. V., Isojärvi J. I. Early hormonal changes during valproate or carbamazepine treatment: a 3-month study. Neurology. 2001 Aug 14;57(3):440–444. doi: 10.1212/wnl.57.3.440. [DOI] [PubMed] [Google Scholar]
  41. Rättyä J., Turkka J., Pakarinen A. J., Knip M., Kotila M. A., Lukkarinen O., Myllylä V. V., Isojärvi J. I. Reproductive effects of valproate, carbamazepine, and oxcarbazepine in men with epilepsy. Neurology. 2001 Jan 9;56(1):31–36. doi: 10.1212/wnl.56.1.31. [DOI] [PubMed] [Google Scholar]
  42. Rättyä J., Vainionpä L., Knip M., Lanning P., Isojärvi J. I. The effects of valproate, carbamazepine, and oxcarbazepine on growth and sexual maturation in girls with epilepsy. Pediatrics. 1999 Mar;103(3):588–593. doi: 10.1542/peds.103.3.588. [DOI] [PubMed] [Google Scholar]
  43. Røste L. S., Taubøll E., Berner A., Isojärvi J. I., Gjerstad L. Valproate, but not lamotrigine, induces ovarian morphological changes in Wistar rats. Exp Toxicol Pathol. 2001 Feb;52(6):545–552. doi: 10.1016/S0940-2993(01)80014-2. [DOI] [PubMed] [Google Scholar]
  44. Stoffel-Wagner B., Bauer J., Flügel D., Brennemann W., Klingmüller D., Elger C. E. Serum sex hormones are altered in patients with chronic temporal lobe epilepsy receiving anticonvulsant medication. Epilepsia. 1998 Nov;39(11):1164–1173. doi: 10.1111/j.1528-1157.1998.tb01307.x. [DOI] [PubMed] [Google Scholar]
  45. Taubøll E., Isojärvi J. I., Harbo H. F., Pakarinen A. J., Gjerstad L. Long-term valproate treatment induces changes in ovarian morphology and serum sex steroid hormone levels in female Wistar rats. Seizure. 1999 Dec;8(8):490–493. doi: 10.1053/seiz.1999.0342. [DOI] [PubMed] [Google Scholar]
  46. Vainionpä L. K., Rättyä J., Knip M., Tapanainen J. S., Pakarinen A. J., Lanning P., Tekay A., Myllylä V. V., Isojärvi J. I. Valproate-induced hyperandrogenism during pubertal maturation in girls with epilepsy. Ann Neurol. 1999 Apr;45(4):444–450. doi: 10.1002/1531-8249(199904)45:4<444::aid-ana5>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
  47. Victor A., Lundberg P. O., Johansson E. D. Induction of sex hormone binding globulin by phenytoin. Br Med J. 1977 Oct 8;2(6092):934–935. doi: 10.1136/bmj.2.6092.934-a. [DOI] [PMC free article] [PubMed] [Google Scholar]
  48. Wallace H., Shorvon S., Tallis R. Age-specific incidence and prevalence rates of treated epilepsy in an unselected population of 2,052,922 and age-specific fertility rates of women with epilepsy. Lancet. 1998 Dec 19;352(9145):1970–1973. doi: 10.1016/S0140-6736(98)04512-7. [DOI] [PubMed] [Google Scholar]
  49. Webber M. P., Hauser W. A., Ottman R., Annegers J. F. Fertility in persons with epilepsy: 1935-1974. Epilepsia. 1986 Nov-Dec;27(6):746–752. doi: 10.1111/j.1528-1157.1986.tb03605.x. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES